Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Synlogic Inc is a biotechnology business based in the US. Synlogic shares (SYBX) are listed on the NASDAQ and all prices are listed in US Dollars. Synlogic employs 84 staff and has a trailing 12-month revenue of around $1.9 million.
Our top pick for
Beginners
Our top pick for
Free trades
Our top pick for
Social traders
| Latest market close | $0.95 |
|---|---|
| 52-week range | $0.83 - $3.20 |
| 50-day moving average | $1.03 |
| 200-day moving average | $1.60 |
| Wall St. target price | $7.60 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-0.97 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.95 from 2022-09-30
| 1 week (2022-09-23) | -1.04% |
|---|---|
| 1 month (2022-09-02) | -9.52% |
| 3 months (2022-07-01) | -10.38% |
| 6 months (2022-03-31) | -60.42% |
| 1 year (2021-10-01) | -68.33% |
|---|---|
| 2 years (2020-10-02) | -52.74% |
| 3 years (2019-10-02) | 2.02 |
| 5 years (2017-09-29) | 19.015 |
| Revenue TTM | $1.9 million |
|---|---|
| Gross profit TTM | $1.8 million |
| Return on assets TTM | -26.21% |
| Return on equity TTM | -51.05% |
| Profit margin | 0% |
| Book value | $1.67 |
| Market capitalisation | $67.4 million |
TTM: trailing 12 months
We're not expecting Synlogic to pay a dividend over the next 12 months.
Synlogic's shares were split on a 1:7 basis on 28 August 2017. So if you had owned 7 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Synlogic shares – just the quantity. However, indirectly, the new 600% higher share price could have impacted the market appetite for Synlogic shares which in turn could have impacted Synlogic's share price.
Over the last 12 months, Synlogic's shares have ranged in value from as little as $0.826 up to $3.2. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Synlogic's is 1.2837. This would suggest that Synlogic's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Synlogic, Inc. , a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotic medicines to treat metabolic and immunological diseases in the United States. Its therapeutic programs include SYNB1618 and SYNB1934 that are orally administered, non-systemically absorbed drug candidates, which are in Phase II clinical trials to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate to treat homocystinuria; SYNB2081 to lower uric acid for the potential treatment of gout; and SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase I clinical trial for the treatment of enteric hyperoxaluria. The company is also developing SYNB1891, an intratumorally administered synthetic biotic medicine that is in Phase I clinical trial to treat solid tumors and lymphoma. It has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. for the research and pre-clinical development of a synthetic biotic medicine for the treatment of inflammatory bowel disease; and Ginkgo Bioworks, Inc.
Looking for a discount broker like Webull that offers something different? Here are some of the top alternatives to consider.
Here are the best renewable energy stocks that should be on your radar to help you grow your green portfolio
Here are 6 manganese stocks that should be on your radar as EV batteries create new demand.
Our list of 10 dividend stocks to watch in 2022.
Everything we know about the YanGuFang International Group IPO, plus information on how to buy in.
Looking to invest in tech? Here’s how to buy shares in the major tech companies, known as FAANG stocks.
A simple guide to buying stocks in your favorite European soccer team.
Steps to owning and managing JUVE, with 24-hour and historical pricing before you buy.
Steps to owning and managing ASR, with 24-hour and historical pricing before you buy.
Steps to owning and managing BVB, with 24-hour and historical pricing before you buy.